ARS Pharmaceuticals (SPRY) Revenue (2022 - 2026)
ARS Pharmaceuticals (SPRY) posted Revenue of $22.7 million for Q1 2026, down 19.25% sequentially from $28.1 million in Q4 2025, and up 184.47% YoY from $8.0 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Revenue (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Revenue for 5 years, with the latest figure at $22.7 million in Q1 2026.
- Quarterly Revenue rose 184.47% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.0 million (up 1.92% YoY) and the FY2025 annual result came in at $84.3 million, down 5.46% from the prior year.
- Revenue declined to $22.7 million in Q1 2026 per SPRY's latest filing, from $28.1 million in the prior quarter.
- Over five years, Revenue peaked at $86.6 million in Q4 2024 and troughed at $10000.0 in Q2 2023.
- A 5-year average of $15.2 million and a median of $2.1 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2024: Revenue slumped 97.84% in 2023, then soared 4900.0% in 2024.
- Over 5 years, Revenue stood at $189000.0 in 2022, then tumbled by 94.71% to $10000.0 in 2023, then jumped by 865710.0% to $86.6 million in 2024, then plunged by 67.56% to $28.1 million in 2025, then declined by 19.25% to $22.7 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $22.7 million, $28.1 million, and $32.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 33.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.66 Mn |
| Mar 31, 2026 | 22.68 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Sep 30, 2025 | 32.50 Mn |
| Jun 30, 2025 | 15.72 Mn |
| Mar 31, 2025 | 7.97 Mn |
| Dec 31, 2024 | 86.58 Mn |
| Sep 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Mar 31, 2023 | 20,000.00 |
| Sep 30, 2022 | 189,000.00 |
| Jun 30, 2022 | 464,000.00 |
| Mar 31, 2022 | 663,000.00 |